Vitrectomy drug alternative continues to impress

Article

The Phase IIb trial assessing the safety and efficacy of microplasmin in patients, showed complete resolution of vitreomacular traction or macular hole without need for vitrectomy surgery, according to a statement from the trial sponsor, ThromboGenics NV.

The Phase IIb trial assessing the safety and efficacy of microplasmin in patients, showed complete resolution of vitreomacular traction or macular hole without need for vitrectomy surgery, according to a statement from the trial sponsor, ThromboGenics NV.

Dr Kirk Packo, Professor and Chairman at the Department of Ophthalmology, Rush University Medical Center in Chicago, US presented the six-month results of the randomized, double-masked, multicentre, dose-evaluation study at the meeting of the American Academy of Ophthalmology (AAO).

The results, consistent with the one-month follow-up data presented at the World Ophthalmology Congress in Hong Kong, demonstrated that a 125µg intravitreal dose of microplasmin treated the condition successfully, so that the need for vitrectomy was bypassed, in approximately one third of cases. Those patients who had achieved disease resolution at one month maintained this improvement at six months. At this time point, visual acuity in patients treated successfully with microplasmin was equal to that of patients who had undergone vitrectomy.

The Phase III trial programme, assessing microplasmin as a treatment for vitreomacular adhesion, is now being finalized. The trial will begin early next year.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.